trending Market Intelligence /marketintelligence/en/news-insights/trending/qSI2mll4STnaZr9VBAQvdA2 content esgSubNav
In This List

US FDA approves new dose of Allergan/Ironwood constipation drug

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Blog

Essential IR Insights Newsletter - Summer July-August 2023

Blog

Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits


US FDA approves new dose of Allergan/Ironwood constipation drug

The U.S. FDA approved a 72 microgram dose of Ironwood Pharmaceuticals Inc. and Allergan PLC's LINZESS for the treatment of chronic idiopathic constipation in adults.

The new dose is expected to be available in the first quarter of 2017. Approval of the new dose was based on the results of a phase 3 trial of 1,223 adults with the disease.

LINZESS is now FDA-approved in three dosages: 290 mcg for patients with irritable bowel syndrome with constipation, and 145 mcg and 72 mcg for adults with chronic idiopathic constipation.